

Hypertension and hypertensive heart disease in African women

Karen Sliwa · Dike Ojji · Katrin Bachelier ·
Michael Böhm · Albertino Damasceno ·
Simon Stewart

Received: 30 July 2013 / Accepted: 2 January 2014 / Published online: 28 January 2014
© Springer-Verlag Berlin Heidelberg 2014

Abstract Hypertension and hypertensive heart disease is one of the main contributors to a growing burden of non-communicable forms of cardiovascular disease around the globe. The recently published global burden of disease series showed a 33 % increase of hypertensive disorders in pregnancy in the past two decades with long-term consequences. Africans, particularly younger African women, appear to be bearing the brunt of this increasing public health problem. Hypertensive heart disease is particularly problematic in pregnancy and is an important contributor to maternal case-fatality. European physicians increasingly need to attend to patients from African descent and need to know about unique

aspects of disease presentation and pharmacological as well as non-pharmacological care. Reductions in salt consumption, as well as timely detection and treatment of hypertension and hypertensive heart disease remain a priority for effective primary and secondary prevention of CVD (particularly stroke and CHF) in African women. This article reviews the pattern, potential causes and consequences and treatment of hypertension and hypertensive heart disease in African women, identifying the key challenges for effective primary and secondary prevention in this regard.

Keywords Hypertension · Africa · Black women · Hypertensive heart disease

K. Sliwa (✉) · S. Stewart
Department of Medicine, Hatter Institute for Cardiovascular
Research in Africa and IIDMM, Faculty of Health Sciences,
Groote Schuur Hospital and University of Cape Town,
Observatory, Cape Town 7925, South Africa
e-mail: sliwa-hahnlek@mdh-africa.org

K. Sliwa · S. Stewart
Soweto Cardiovascular Research Unit, University of the
Witwatersrand, Johannesburg, Republic of South Africa

K. Sliwa · S. Stewart
NHMRC Centre for Research Excellence to Reduce Inequality
in Heart Disease, Preventative Cardiology, Baker IDI Heart and
Diabetes Institute, Melbourne, Australia

D. Ojji
Cardiology Unit, Department of Medicine, University of Abuja
Teaching Hospital, Gwagwalada, Abuja, Nigeria

K. Bachelier · M. Böhm
Klinik für Innere Medizin III, Kardiologie, Angiologie und
Internistische Intensivmedizin, Universitätsklinikum des
Saarlandes, Homburg/Saar, Germany

A. Damasceno
Faculty of Medicine, Eduardo University, Maputo, Mozambique

Hypertension: a global epidemic

The global impact of elevated blood pressure (BP)/hypertension is profound, being responsible for more deaths worldwide than any other cardiovascular risk factors including tobacco use, obesity and lipid disorders [1, 2]. The recently published Global Burden of Disease Study showed a marked increase in years lived with disabilities (YLDs) for all ages of 33 % from 1990 to 2010 due to hypertensive disorders of pregnancy. In the USA hypertension still contributes to the greatest population attributable risk for all-cause (30 %) and cardiovascular disease (CVD) related deaths (40 %) [3]. Moreover, longitudinal, population and cohort studies demonstrate a continuous relationship between elevated BP and increased risk of cardiovascular events that defy simple thresholds for applying treatment [4]. As such, hypertension is a key contributor to a global epidemic of CVD that is indirectly manifested via a range of conditions such as stroke, chronic heart failure (CHF), acute coronary syndromes and chronic kidney disease [5–8]. In


spite of the profound contribution of hypertension to the global burden of non-communicable forms of CVD, efforts to control the massive influence of uncontrolled hypertension are still limited. Beyond the developed world, 80 % of worldwide CVD-related deaths now occur in low- and middle-income countries (LMIC) [5]. Unlike in developed countries [5–8], in LMIC, morbid and fatal CVD-related events typically occur at a younger age and affect more women, commonly in pregnancy, thereby exerting a more profound impact on the family unit and the workforce [9, 10]. In the immediate future, this adverse impact is likely to rise with predictions that non-communicable forms of CVD will become the leading cause of death and disability globally by 2020 [5]. These trends reflect a growing need to truncate a disproportionate burden of CVD in vulnerable communities with hypertension as a key target.

Hypertension in Africa

The complex challenge preventing, or at least truncating, the next epidemic of CVD with hypertension representing a

major target is particularly problematic for the diverse peoples of the African continent and, specifically, those living in sub-Saharan Africa. In contrast to established market economies with good clinical medical data surveillance systems (in particular northern Europe and North America), comprehensive data on the burden of hypertension in Africa are often lacking or conflicting (representing the heterogeneous nature of its people, lifestyles and economic development) [11]. Throughout Africa, a formal system of medical information is unavailable in most countries. Local community studies and single centre health records are often used to obtain information about population health. However, a systematic review of 25 studies (>400 subjects in each) from ten sub-Saharan countries during the period 1987–2004 showed a reported prevalence of hypertension in the region, ranging from 13 to 48 %, with lower prevalence in rural versus urban gradients linked to epidemiologic transition and a large burden among women of African descent [12]. Figure 1 summarizes the estimated rate of hypertension by the World Health Organisation in sub-Saharan Africa according to country [2]. Population prevalence estimates for the region ranging from 33.9 % in Eritrea to 52.5 % in Niger.

Fig. 1 World Health Organisation estimates of prevalence of hypertension in major populations across Africa. Estimated proportion (%) of adult men (blue) and women (red) [62]



Hypertension in African women

Despite a wealth of data to describe the pattern of hypertension in those of Afro-American descent, supplemented by a number of single centre (hospital and primary care) registries in Africa focussing on presentations related to hypertension [13–16], there is a paucity of analyses and reporting based on gender in particular black African women. Given the size of the populations at risk, understanding the specific risk factors, progression of hypertension to hypertensive heart disease with end-organ damage and the consequences of largely undetected and untreated hypertension in African women are keys to minimise the emergence of non-communicable forms of CVD, both from a primary and secondary prevention perspective.

Hypertension in the black African population is considered a distinct biological entity. Not only do Africans develop more hypertension, but also compared to other ethnic groups hypertension in Blacks is often more severe [17] and more resistant to treatment [12]. Hypertensive target organ damage in Ghanaian civil servants with hypertension is more likely to be fatal on an age-adjusted basis.

Studies on possible pathophysiological mechanisms are not yet conclusive, particularly in respect to gender-based heterogeneity. However, observed gender-based differences in the underlying prevalence and characteristics of hypertension in black Africans are often marked. For example, a contemporary registry that captured data from 1311 consecutive primary care patients (99 % African), from two primary care clinics in the townships of Soweto, South Africa, included a predominance of women (862 cases) with 66 % of those women demonstrating higher overall BP levels compared to men [13]. Overall, compared


to their male counterparts, women, who were 3 years older than men were more likely to report a family history of any form of heart disease, were more likely to have a personal past history of hypertension and were far more likely to be obese (42 versus 14 %; OR 4.54, 95 % CI 3.33–5.88).

Hypertensive heart disease in African women

In the Heart of Soweto hospital registry which captured detailed information on >6000 de novo presentations (5328 with confirmed heart disease) to the Cardiology Unit of the Baragwanath Hospital, which services a community in profound epidemiological transition [10, 12–15], African women were the single biggest contributor to case presentations (2863—54 %) with many relatively young cases on non-communicable heart disease (see Fig. 2). Of these, 575 (20 %) presented with a primary diagnosis of hypertension and a further 1196 (42 %) had a secondary diagnosis of hypertension. Among the latter, hypertensive heart failure (682/1196—57 %, mean age 60 ± 14 years) was the most common manifestation of hypertensive heart disease [10]. Interestingly, level of education and non-communicable risk factors such as family history of CVD, smoking, being obese and Type II diabetes correlated with advance disease.

Historically, these data contrast with that collected in Nigeria in the 1960s and 1970s showing a higher prevalence of hypertension in men than in women at least up to the age of 40 years when the prevalence equalized [18, 19]. However, a more contemporary report from rural Nigeria showed that amongst 858 cases of hypertension, more than two-thirds were female suggesting a possible shift in epidemiology [20].

Fig. 2 The cyclical challenge of preventing maternal and inter-generational susceptibility to hypertension and hypertensive heart disease in African women



Proposed mechanisms for increased susceptibility to hypertension

A number of studies have documented a change of lifestyle in sub-Saharan Africa [21, 22] contributing to an increasing prevalence of hypertension—particularly in women and those living in urban centres. As shown in the Heart of Soweto Primary Care Registry [23], obesity was the most common contributor to hypertensive heart disease, especially in young women moving from rural to urban areas.

Birth weight for gestational age, an indicator for foetal growth, has been identified as an independent predictor of elevated BP in adulthood in a number of studies but the strength in this relationship remains not entirely clear [24]. There is a paucity of data investigating this relationship that has been published in those of black African descent. Kruger and colleagues investigated the determinants of overweight and obesity among 10- to 15-year-old school children in the North West Province, South Africa in the THUSA BANA (Transition and Health during Urbanisation of South Africans; BANA, children) study [25]. They found a low prevalence of excess weight (7.8 %) amongst the 1257 children studied. However, the Bogalusa cohort studies followed up 158 children from a USA cohort of 48 black and 47 white boys, as well as 41 black and 49 white girls for a period of 15–17 years [26]. Birth weights were significantly lower ($p < 0.001$) in black boys and girls than in whites who developed higher BPs as adolescents. In regression analysis, birth weight accounted for ethnic differences in adolescent BP. Running the regression models for black boys and girls separately showed no difference. Post-natal or first year growth seems to have a possibly independent effect compared to intrauterine growth performance. This type of ‘catch up growth’ across centiles of growth trajectories has also been associated with the development of coronary artery disease in later life [27]. The Bogalusa cohort showed that the timing of the somatic growth on vascular development was important as it was only evident between birth and 4–5 years, with no significant additional impact in growth from 4–5 to 15 years.

These are all interesting and important findings. However, much larger and more comprehensive fully longitudinal data sets are needed with relevant standardized measures at several time points included. If these data can be reproduced in other studies and, in particular, in African adolescents and women it would be possible to reduce the excess prevalence of hypertension currently observed in black Americans and black Africans via the combination of promoting appropriate early growth and then restraining excess weight gain by adolescence.

Pregnancy and hypertension

Hypertension occurring in pregnancy can manifest as pre-existing chronic hypertension, gestational hypertension, pre-eclampsia and eclampsia (Fig. 2). Hypertensive disorders are responsible for 14 % of the more than 4687 cases of maternal death in South Africa reported for 2008–2010 (<http://www.hst.org.za/saving-mothers-2008-2010>) and, therefore, require special consideration and attention. Chronic hypertension prior to pregnancy is increasing due to the world-wide obesity epidemic and is prevalent in 3 % of all US pregnant women [28]. The prevalence in African women is unknown. However, the recently published systemic analysis for the Global Burden of Disease Study on YLDs for 1160 sequelae of 289 diseases and injuries: 1990–2010 documented a 33 % increase in hypertensive disorders of pregnancy worldwide [17].

In a tertiary hospital-based study in Nigeria, hypertension was seen in 9.8 % of 409 pregnant women studied at booking and this rose to 26.2 % at delivery [17]. In another hospital-based single centre study in Nigeria, chronic pre-existing hypertension was seen in 4.5 % of 442 hypertensive subjects studied [17]. Chronic hypertension leads to increased frequency of pre-eclampsia (17–25 % versus 3–5 % in the general population), as well as placental abruption, foetal growth restriction and preterm birth [28]—all common problems occurring in pregnant African women. Endothelial dysfunction associated with levels of circulating endothelial cells, circulating progenitor cells and plasma von Willebrand factor have been reported recently in hypertension in pregnancy [29].

A particularly important form of CVD in African women is peripartum cardiomyopathy (PPCM). This condition occurs in 1:1000 women in Africa and is a diagnosis of exclusion with a large differential diagnosis [30, 31]. However, there is no agreement on the exclusion of hypertension and pre-eclampsia. Unfortunately, the inclusion of patients with varying degrees of gestational hypertension, in index as well as prior pregnancies, has contributed greatly to the discrepancy in reported characteristics of PPCM. Studies comprising greater proportions of patients with pre-eclampsia and severe hypertension tend to have a far greater frequency of PPCM cases presenting in the last month of pregnancy [32]. In contrast, studies that have attempted to minimize the inclusion of patients with pre-eclampsia and only including milder forms of hypertension show a clear postpartum peak in the presentation of PPCM with reported onset of symptoms most commonly being 1–2 months postpartum [30, 33, 34]. The Study Group on PPCM has therefore not reached consensus on the inclusion/exclusion of patients with pre-eclampsia and severe hypertension as requisite to the diagnosis of PPCM [31].

Transition from hypertension to hypertensive heart disease

The presence of left ventricular hypertrophy (LVH) adversely affects the prognosis of patients with arterial hypertension. In the Framingham Study, cardiovascular mortality among patients with arterial hypertension and increased left ventricular mass measured by echocardiography was double in comparison with patients with normal mass [35]. LVH can be characterized by geometric subtypes, based on LV mass index (LVMI) for body size and relative wall thickness (RWT), which further refines cardiovascular risk assessment. Patients with concentric LVH, defined by increased RWT and LVMI, have been shown to have worse clinical outcomes compared to patients with other subtypes of LV geometric pattern [36]. A recent study on gender differences in LV size and geometric pattern of 676 newly presenting adults in Nigeria showed that more women (26.9 %) had concentric LVH compared to men (20.1 %; $p = 0.04$) with posterior wall thickness, and weight being predictors of this LV geometric pattern [37]. These data are supported by earlier data published by Weinberg and colleagues who also observed that hypertensive women had a greater degree of increase in LV wall thickness and concentric LVH [38]. Gender-related differences in serum aldosterone correlating positively with LVH in women were also reported [38], but not separately investigated in African women. In the Heart of Soweto Study almost 40 % of patients presented with left ventricular hypertrophy (LVH) confirmed by echocardiography. Moreover, two-thirds of cases had previously undiagnosed heart disease (predominantly HF and renal failure) [39]. Significantly, these findings had been predicted because of worryingly low levels of detection, treatment and control of HT in urban sub-Saharan Africa [40].

Fortunately, hypertension is an easily detectable condition that can be readily controlled with treatments that are not only inexpensive, but relevant to salt-sensitive black Africans (e.g. thiazides and dihydropyridine calcium antagonists [41]) in whom regression of LVH is achievable—see below [42]. In this context, it is clear from our own and previous African and African-American studies [43] that hypertension is an extremely important antecedent for CHF. However, the progression from concentric LVH to CHF has not well been defined in African women and Africans altogether.

Early detection of hypertensive heart disease via 12-lead ECG

The 12-lead ECG remains an important diagnostic tool for detecting manifestations of hypertensive heart disease [44].

However, a recent publication [45] describing the electrocardiographic findings of African adults found to be both free from heart disease and any underlying cardiac dysfunction/pathology via echocardiography, requires comment. Of the 387 urban South Africans studied 199 (51 %) had an ECG ‘abnormality’ and 67 ECGs (17 %) had major and minor abnormalities by Minnesota coding. Sokolow-Lyon Index voltage exceeding 38 mm indicative of LVH was more prominent in males than in females (23.6 versus 6.4 %; OR 4.5, 95 % CI 2.3–8.5). These findings are important as ‘false positive’ ECGs can be a confounding factor indicative of underlying heart disease but representing normal ECG variants in the African population [45]. A cost-effective way to detect advanced heart disease in patients with hypertension (potentially using a combination of 12-lead ECG and N-terminal brain natriuretic peptide [46]) in the primary care setting is yet to be determined, but is of great importance given the apparent limitations of the ECG in this context.

Managing hypertension/hypertensive heart disease in African women

Detection of individuals

Although hypertension represents an important and preventable risk factor for more advanced forms of CVD, it cannot be considered in isolation. As described in a recent review of the global management of hypertension [6] and consistent with the approach adopted in high income countries, the World Health Organization’s Choosing Interventions that are Cost-Effective program recommends an absolute risk approach to risk factor management in LMIC [47]. In practical terms, this means actively treating those with multiple risk factors and, therefore, intrinsically at higher risk unless presenting with an extreme individual value—e.g. a BP >180/100. Any profiling of African women with suspected hypertension should therefore incorporate, where possible, a basic assessment of the affected individual’s age, family history, lipid profile, smoking status and anthropometrics. It should also include noting the caveats described above, a 12-lead ECG to determine the potential presence of LVH, in addition to screening for other signs of end-organ damage including proteinuria/micro-albuminuria, bearing in mind that Africans often present with more advanced forms of hypertensive disease [39, 48]. The challenge of adequately controlling BP and other risk factors in this setting has been highlighted by the recently reported HiHi study of hypertensive black Africans in Cape Town townships [22].

Although there are internet-based risk profiling algorithms, the use of chart-based calculations is still a

potentially popular and effective means to guide effective BP management [49]. From a life-style perspective, it is important to note that being overweight is culturally acceptable (and even desirable) in many African countries. Regardless, efforts to achieve weight reduction, coupled with a low-salt diet as well as lower saturated fat intake (particularly in urban areas where traditional diets have been replaced with salt, fat and sugar-enriched diets) are often mandatory [50]. Regardless of the setting and chosen pharmacological agents, a recent Cochrane review of BP management in primary care [51] highlighted the importance of a structured and intensive care approach to effectively lowering BPs in affected individuals and this applies equally to the African context. For example, while it is generally accepted that African Americans suffer more severely from the consequences of hypertension, in the hypertension detection and follow-up program (the largest and most influential study in the aforementioned Cochrane Review), African-American men benefited more than their white counterparts [52].

Role of salt

Salt is known to affect blood pressure via a linear association. Average salt intake in South African adults is 8.1 g/day and much higher than the 4–6 g/day recommended by the World Health Organisation [53]. Much of salt consumption arises from non-discretionary intake such as bread, margarine and soup mixes [54]. As highlighted in a recent publication by Bertram and colleagues, proposed reduction in selected foods, such as bread, would decrease the average salt intake by 0.85 g/person/day. This would result in 7400 fewer cardiovascular death and 4300 less fatal strokes per annum, with substantial cost-saving to the individual, family and society. As such, the broad evidence suggests that a reduced sodium diet has an effect on hypertension equivalent to that of first-line drug treatment with a diuretic [55].

Pharmacological and non-pharmacological management

With respect to medical therapy, while there is clear evidence to demonstrate that every anti-hypertensive agent is effective in lowering BPs to reduce primary and secondary events in a roughly linear fashion in all races [4], there are clearly defined population groups which require special consideration [56]. For example, there is some evidence that African Americans achieve a lesser reduction in BP when beta-blockers, angiotensin receptor inhibitors and angiotensin receptor blockers are applied in mono-therapy form, compared to white Americans [56]. The introduction of an additional diuretic appears to attenuate this lack of

effect [57–59]. Conversely, the ALLHAT trial, including more than 15,000 subjects of African descent, showed that an ACE inhibitor was less effective in lowering BP, compared to a thiazide diuretic or calcium channel antagonist, resulting in 20–40 % more CVD events (including CHF and stroke) [57]. In a study of 125 hypertensive Africans (68 % female), Libhaber and colleagues demonstrated that initiating therapy with 1.5 mg of indapamide SR and then adding 4 mg of perindopril is equally as effective as amlodipine therapy alone at reducing BP and modifying target organ damage [41]. Although treating hypertensive female patients has become very easy with different choices of medications, this can pose a problem in pregnancy as few medications, especially the short-acting calcium channel blocker (Nifedipine) and Alpha methyl dopa, have been found to be safe in pregnancy.

The recent development of the renal sympathetic denervation therapy might have important implications for a population group, often presenting with severe hypertension and requiring multiple drug therapy, without achieving sufficient control. The recent publication by Vogel B et al. [60] highlights experiences with renal denervation in the real world set up.

Practical aspects of BP measurement in Africa

The recent development of a low cost solar-powered blood-pressure device may be a step in the right direction in tackling the increasing burden of hypertension in sub-Saharan Africa [61]. The WHO commissioned the development of a manual and/or automated, non-mercury, solar-powered, accurate and robust device for low-resource settings, making it affordable for many and will, hopefully, equip resource-poor health-care systems to readily identify and treat at-risk women.

Perspectives

In conclusion, there is convincing evidence that hypertension is becoming increasingly prevalent in African women due to epidemiological transition with geographic and socio-economic gradients evident across the African continent. Moreover, hypertensive heart disease typically affects women at a far younger age in sub-Saharan Africa than that observed in high income countries. Hypertensive heart disease is particularly problematic in pregnancy and is an important contributor to maternal case-fatality. Population-wide reduction in salt consumption, as well as timely detection and treatment of hypertension and hypertensive heart disease, remains a priority for effective primary and secondary prevention of CVD (particularly stroke and CHF) in African women. Relatively cheap

treatment options are available to effectively treat affected women. The challenge is to establish cost-effective and sustainable screening and subsequent management programs in the community to ensure that as many affected African women are detected and treated in a timely manner. This will entail targeting women at a much younger age than would be expected in a high income setting.

Acknowledgements KS receives support by unconditional research grants from the University of Cape Town, the University of the Witwatersrand, Maurice Hatter Foundation, The Medical Research Council South Africa, Servier, and the Medtronic Foundation. SS and KS are supported by the Centre of Research Excellence to Reduce Inequality in Heart Disease, NHMRC of Australia. KS, MB and KB are supported by a grant from the South African Research Foundation and the BMBF.

Conflict of interest None of the authors has a conflict of interest related to this manuscript.

References

- He FJ, MacGregor GA (2007) Blood pressure is the most important cause of death and disability in the world. *Eur Heart J Suppl* 9:B23–B28
- World Health Organization (2008) 2008–2013 Action plan for the global strategy for the prevention and control of non-communicable diseases. <http://www.who.int/nmh/actionplan-PC-NCD-2008.pdf>. Accessed July 2012
- Yang Q, Cogswell ME, Flanders WD, Hong Y, Zhang Z, Loustalot F, Gillespie C, Merritt R, Hu FB (2012) Trends in cardiovascular health metrics and associations with all-cause and CVD mortality among US adults. *JAMA* 307:1273–1283
- Law M, Morris J, Wald N (2009) Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies. *BMJ* 338:1245–1253
- Abegunde DO, Mathers CD, Adam T, Ortegon M, Strong K (2007) The burden and costs of chronic diseases in low-income and middle-income countries. *Lancet* 370:1929–1938
- Sliwa K, Stewart S, Gersh BJ (2011) Hypertension a global perspective. *Circulation* 123:2892–2896
- Gersh BJ, Sliwa K, Mayosi BM, Yusuf S (2010) Novel therapeutic concepts: the epidemic of cardiovascular disease in the developing world: global implications. *Eur Heart J* 31:642–648
- Mayosi BM, Flisher AJ, Lalloo UG, Sitas F, Tollman SM, Bradshaw D (2009) The burden of non-communicable diseases in South Africa. *Lancet* 374:934–947
- Njelekela MA, Mpembeni R, Muhihi A, Mligiliche NL, Spiegelman D, Hertzmark E, Liu E, Finkelstein JL, Fawzi WW, Willett WC, Mtabaji J (2009) Gender-related differences in the prevalence of cardiovascular disease risk factors and their correlates in urban Tanzania. *BMC Cardiovasc Disord* 9:30
- Stewart S, Carrington M, Pretorius S, Methusi P, Sliwa K (2011) Standing at the crossroads between new and historically prevalent heart disease: effects of migration and socio-economic factors in the Heart of Soweto cohort study. *Eur Heart J* 32:492–499
- Cooper RS, Osotimehin B, Kaufman JS, Forrester T (1998) Disease burden in sub-Saharan Africa: what should we conclude in the absence of data? *Lancet* 351:208–210
- Addo J, Smeeth L, Leon DA (2007) Hypertension in sub-Saharan Africa: a systematic review. *Hypertension* 50:1012–1018
- Stewart S, Carrington MJ, Pretorius S, Ogah OS, Blauwet L, Antras-Ferry J, Sliwa K (2012) Elevated risk factors but low burden of heart disease in urban African primary care patients: a fundamental role for primary prevention. *Int J Cardiol* 158:2005–2010
- Selassie A, Wagner CS, Laken ML, Ferguson ML, Ferdinand KC, Egan BM (2011) Progression is accelerated from prehypertension to hypertension in blacks. *Hypertension* 58:579–587
- Sliwa K, Wilkinson D, Hansen C, Ntyintyane L, Tibazarwa K, Becker A, Stewart S (2008) Spectrum of heart disease and risk factors in a black urban population in South Africa (the Heart of Soweto Study): a cohort study. *Lancet* 371:915–922
- Olatunbosun ST, Kaufman JS, Cooper RS, Bella AF (2000) Hypertension in a black population: prevalence and biosocial determinants of high blood pressure in a group of urban Nigerians. *J Hum Hypertens* 14:249–257
- Salako BL, Ogah OS, Adebisi AA, Adedapo KS, Bekibebe CO, Oluleye TS, Okpechi I (2007) Unexpectedly high prevalence of target-organ damage in newly diagnosed Nigerians with hypertension. *Cardiovasc J Afr* 18:77–83
- Kramer H, Han C, Post W, Goff D, Diez-Roux A, Cooper R, Jinagouda S, Shea S (2004) Racial/ethnic differences in hypertension and hypertension treatment and control in the multi-ethnic study of atherosclerosis (MESA). *Am J Hypertens* 17:963–970
- Akinkugbe OO, Ojo AO (1968) The systemic blood pressure in a rural Nigerian population. *Trop Geogr Med* 20:347–356
- Ogah OS (2006) Hypertension in sub-Saharan African populations: the burden of hypertension in Nigeria. *Ethn Dis* 16:765
- Onwubere BJ, Ejim EC, Okafor CI, Emehel A, Mbah AU, Onyia U, Mendis S (2011) Pattern of blood pressure indices among the residents of a rural community in South East Nigeria. *Int J Hypertens* 2011:621074
- Peer N, Steyn K, Dennison CR, Levitt NS, Nyo MT, Nel JH, Commerford PJ, Fourie JM, Hill MN (2008) Determinants of target organ damage in black hypertensive patients attending primary health care services in Cape Town: the Hi–Hi study. *Am J Hypertens* 21:896–902
- Stewart S, Libhaber E, Carrington M, Damasceno A, Abbasi H, Hansen C, Wilkinson D, Sliwa K (2011) The clinical consequences and challenges of hypertension in urban-dwelling black Africans: insights from the Heart of Soweto Study. *Int J Cardiol* 146:22–27
- Huxley R, Neil A, Collins R (2002) Unravelling the fetal origins hypothesis: is there really an inverse association between birthweight and subsequent blood pressure? *Lancet* 360:659–665
- Kruger R, Kruger HS, Macintyre UE (2006) The determinants of overweight and obesity among 10- to 15-year-old schoolchildren in the North West Province, South Africa—the THUSA BANA (Transition and Health during Urbanisation of South Africans; BANA, children) study. *Public Health Nutr* 9:351–358
- Cruickshank JK, Mzayek F, Liu L, Kieltyka L, Sherwin R, Webber LS, Srinivasan SR, Berenson GS (2005) Origins of the “black/white” difference in blood pressure: roles of birth weight, postnatal growth, early blood pressure, and adolescent body size: the Bogalusa heart study. *Circulation* 111:1932–1937
- Barker DJP (1998) Mothers, babies and health in later life, 2nd edn. Churchill Livingstone, pp 1–127
- Seely EW, Ecker J (2011) Clinical practice. Chronic hypertension in pregnancy. *N Engl J Med* 365:439–446
- Karthikeyan VJ, Blann AD, Baghdadi S, Lane DA, Gareth Beevers D, Lip GY (2011) Endothelial dysfunction in hypertension in pregnancy: associations between circulating endothelial cells, circulating progenitor cells and plasma von Willebrand factor. *Clin Res Cardiol* 100:531–537

30. Sliwa K, Forster O, Libhaber E, Fett JD, Sundstrom JB, Hilfiker-Kleiner D, Ansari AA (2006) Peripartum cardiomyopathy: inflammatory markers as predictors of outcome in 100 prospectively studied patients. *Eur Heart J* 27:441–446
31. Sliwa K, Hilfiker-Kleiner D, Petrie M, Mebazaa A, Pieske B, Buchmann E, Regitz-Zagrosek V, Schaufelberger M, Tavazzi B, van Veldhuisen DJ, Watkins H, Shah AJ, Seferovic PM, Elkayam U, Pankuweit S, Papp Z, Mouquet F, McMurray J (2010) Current state of knowledge on aetiology, diagnosis, management, and therapy of peripartum cardiomyopathy: a position statement from the Heart Failure Association of the European Society of Cardiology Working Group on Peripartum Cardiomyopathy. *Eur J Heart Fail* 12:767–778
32. Elkayam U, Akhter MW, Singh H, Khan S, Bitar F, Hameed A, Shotan A (2005) Pregnancy-associated cardiomyopathy: clinical characteristics and a comparison between early and late presentation. *Circulation* 111:2050–2055
33. Duran N, Gunes H, Duran I, Biteker M, Ozkan M (2008) Predictors of prognosis in patients with peripartum cardiomyopathy. *Int J Gynaecol Obstet* 101:137–140
34. Fett JD, Christie LG, Carraway RD, Murphy JG (2005) Five-year prospective study of the incidence and prognosis of peripartum cardiomyopathy at a single institution. *Mayo Clin Proc* 80:1602–1606
35. Levy D, Garrison RJ, Savage DD, Kannel WB, Castelli WP (1990) Prognostic implications of echocardiographically determined left ventricular mass in the Framingham heart study. *N Engl J Med* 322:1561–1566
36. Koren MJ, Ulin RJ, Koren AT, Laragh JH, Devereux RB (2002) Left ventricular mass change during treatment and outcome in patients with essential hypertension. *Am J Hypertens* 15:1021–1028
37. Weinberg EO, Thienelt CD, Katz SE, Bartunek J, Tajima M, Rohrbach S, Douglas PS, Lorell BH (1999) Gender differences in molecular remodeling in pressure overload hypertrophy. *J Am Coll Cardiol* 34:264–273
38. Vasan RS, Evans JC, Benjamin EJ, Levy D, Larson MG, Sundstrom J, Murabito JM, Sam F, Colucci WS, Wilson PW (2004) Relations of serum aldosterone to cardiac structure: gender-related differences in the Framingham Heart Study. *Hypertension* 43:957–962
39. Stewart S, Wilkinson D, Hansen C, Vaghela V, Mvungi R, McMurray J, Sliwa K (2008) Predominance of heart failure in the Heart of Soweto Study cohort: emerging challenges for urban African communities. *Circulation* 118:2360–2367
40. Opie LH, Seedat YK (2005) Hypertension in sub-Saharan African populations. *Circulation* 112:3562–3568
41. Libhaber EN, Libhaber CD, Candy GP, Sliwa K, Kachope J, Hlatshwayo NM, Puane MO, Woodiwiss AJ, Norton GR, Essop MR, Sareli P (2004) Effect of slow-release indapamide and perindopril compared with amlodipine on 24-hour blood pressure and left ventricular mass in hypertensive patients of African ancestry. *Am J Hypertens* 17:428–432
42. Skudicky D, Sareli P, Libhaber E, Candy G, Radevski I, Valtchanova Z, Tshela E, Thijs L, Wang JG, Staessen JA (2002) Relationship between treatment-induced changes in left ventricular mass and blood pressure in black African hypertensive patients: results of the Baragwanath Trial. *Circulation* 105:830–836
43. Kotchen TA, Kotchen JM, Grim CE, Krishnaswami S, Kidambi S (2009) Aldosterone and alterations of hypertension-related vascular function in African Americans. *Am J Hypertens* 22:319–324
44. Rodrigues SL, Angelo LC, Baldo MP, Dantas EM, Barcelos AM, Pereira AC, Krieger JE, Mill JG (2013) Detection of left ventricular hypertrophy by the R-wave voltage in lead aVL: population-based study. *Clin Res Cardiol* 102:653–659
45. Sliwa K, Lee G, Carrington M, Obel P, Okreglicki A, Stewart S (2013) Redefining the ECG in urban South Africans: electrocardiographic findings in heart disease-free Africans. *Int J Cardiol* 167:2204–2209
46. Galasko G, Collinson PO, Barnes SC, Gaze D, Lahiri A, Senior R (2007) Comparison of the clinical utility of atrial and B type natriuretic peptide measurement for the diagnosis of systolic dysfunction in a low-risk population. *J Clin Pathol* 60:570–572
47. Murray CJ, Lauer JA, Hutubessy RC, Niessen L, Tomijima N, Rodgers A, Lawes CM, Evans DB (2003) Effectiveness and costs of interventions to lower systolic blood pressure and cholesterol: a global and regional analysis on reduction of cardiovascular-disease risk. *Lancet* 361:717–725
48. Kolo P, Omotoso A, Katibi I, Sanya E, Adamu U, Fasae A, Aigbe I (2008) Gender differences in left ventricular size and geometric pattern of hypertension subjects. *Cardiology* 4:11–15
49. Montgomery AA, Fahey T, Peters TJ, MacIntosh C, Sharp DJ (2000) Evaluation of computer based clinical decision support system and risk chart for management of hypertension in primary care: randomised controlled trial. *BMJ* 320:686–690
50. Steyn K, Fourie J, Temple N (2006) Chronic diseases of lifestyle in South Africa: 1995–2005. South African Medical Research Council, Cape Town
51. Glynn LG, Murphy AW, Smith SM, Schroeder K, Fahey T (2010) Interventions used to improve control of blood pressure in patients with hypertension. *Cochrane Database Syst Rev* 3:CD005182
52. Shulman N, Tuttle E Jr, Entwisle G, Apostolides A, Oberman A, Schnaper HW, Kass EH, Taylor JO, Polk BF, Stamler J (1988) Persistence of reduction in blood pressure and mortality of participants in the Hypertension Detection and Follow-up Program. *JAMA* 259:2113–2122
53. Charlton KE, Steyn K, Levitt NS, Zulu JV, Jonathan D, Veldman FJ, Nel JH (2005) Diet and blood pressure in South Africa: intake of foods containing sodium, potassium, calcium, and magnesium in three ethnic groups. *Nutrition* 21:39–50
54. Bertram MY, Steyn K, Wentzel-Viljoen E, Tollman S, Hofman KJ (2012) Reducing the sodium content of high-salt foods: effect on cardiovascular disease in South Africa. *S Afr Med J* 102:743–745
55. MacGregor GA, Markandu ND, Best FE, Elder DM, Cam JM, Sagnella GA, Squires M (1982) Double-blind randomised crossover trial of moderate sodium restriction in essential hypertension. *Lancet* 1:351–355
56. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL, Jones DW, Materson BJ, Oparil S, Wright JT Jr, Roccella EJ (2003) The seventh report of the joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure. *JAMA* 289:2560–2572
57. ALLHAT Collaborative Research Group (2002) Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). *JAMA* 288:2981–2997
58. Douglas JG, Bakris GL, Epstein M, Ferdinand KC, Ferrario C, Flack JM, Jamerson KA, Jones WE, Haywood J, Maxey R, Ofili EO, Saunders E, Schiffrin EL, Sica DA, Sowers JR, Vidt DG (2003) Management of high blood pressure in African Americans: consensus statement of the Hypertension in African Americans Working Group of the International Society on Hypertension in Blacks. *Arch Intern Med* 163:525–541
59. Cushman WC, Reda DJ, Perry HM, Williams D, Abdellatif M, Materson BJ (2000) Regional and racial differences in response to antihypertensive medication use in a randomized controlled trial of men with hypertension in the United States. Department

- of Veterans Affairs Cooperative Study Group on Antihypertensive Agents. *Arch Intern Med* 160:825–831
60. B Vogel, Kirschberger M, Zeier M. (2013). Renal sympathetic denervation therapy in the real world: results from the Heidelberg registry. *Clin Res Cardiol* Oct 15 (Epub ahead of print)
61. Sliwa K, Stewart S (2011) A low-cost solar-powered blood-pressure device. *Lancet* 378:647–648
62. World Health Organization (2011) Noncommunicable disease country specific profiles 2011 (WHO Global Report)